Overview of the drug development pipeline for cystitis
Cystitis is the inflammation of the bladder usually caused by a bladder infection. It is a common type of urinary tract infection. Women are more often affected by cystitis than men. UTI happens when bacteria enter the bladder or urethra and begin to multiply. It could also happen with naturally occurring bacteria in the body that become imbalanced. These bacteria lead to an infection and cause inflammation. Cystitis can either be acute or interstitial. Acute cystitis is a case of cystitis that occurs suddenly. Interstitial cystitis is a chronic or long-term case of cystitis that affects multiple layers of bladder tissue. Both acute and interstitial cystitis have a range of possible causes. Uncomplicated cystitis refers to a lower UTI in either men or nonpregnant women. The incidence of UTI is 12% in women based on self-reported annual incidences. Since UTI is estimated to occur with as a frequency as 0.7 infections per person per year. Fifty percent of females will have at least one UTI at some stage in their life. Consequently, with rising incidences of cystitis, the need for drug development for cystitis is expected to rise in the upcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for cystitis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of cystitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
Therapeutic assessment of the drug development pipeline for cystitis by route of administration
The intravesical route of administration (ROA) involves the application of the drug directly into the bladder, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for cystitis by therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for cystitis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
What are the drug molecules in the various development stages for cystitis?
What are the companies that are currently involved in the development of drug molecules for cystitis?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.